Alerts
PDF
Other content recommended for you
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Update on disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Rhomboencephalitis
- ▼Dimethyl fumarate for relapsing-remitting multiple sclerosis
- Cortical abnormalities on MRI: what a neurologist should know
- Neurodegeneration in multiple sclerosis and neuromyelitis optica
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
- X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline